Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the link between obesity and cancer.
Clifford A. Hudis, MD, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, discusses the link between obesity and cancer.
Hudis says the problem of obesity in the United States is a relatively new issue and has profound medical consequences. Many people know that obesity can lead to arthritis, diabetes and hypertension, but obesity can also cause pancreatitis, gallstones, reflux esophagitis and other ailments including cancer, Hudis says.
Researchers have known that obesity was associated with some specific cancers, such as uterine cancer and breast cancer but they are now discovering that obesity is also associated with colon cancer and high-grade prostate cancers.
Hudis says the reason obesity is associated with cancer is the biochemical reactions that take place when a patient is obese. There are inflammatory cellular structures within the fat tissue that produce inflammatory mediators, which activate aromatase. The activation of aromatase is associate with both breast cancer and endometrial cancer, Hudis says.​
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.